NCT00293410View on ClinicalTrials.gov

Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2010

Conditions
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic/Myeloproliferative Diseases
Interventions
DRUG

clofarabine

DRUG

cyclophosphamide

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00293410 - Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders | Biotech Hunter | Biotech Hunter